Sun Pharma drug gets US nod

NEW DELHI: Drug firm Sun Pharma on Tuesday said it has received tentative approval from US health regulator to sell a generic version of Rilutek tablets, used in treating central nervous system diseases, in the American market. The Mumbai-based firm has received a tentative approval for abbreviated new drug application (ANDA) for a generic version of Rilutek tablets in 50 mg strength, Sun Pharmaceutical Industries said in a statement.

Rilutek tablets, a Sanofi Aventis product, has annual sales of nearly $50 million in the United States. The generic version of the tablets contain Riluzole Hydrochloride in the strength of 50 mg, it said.